Juno Therapeutics, Inc. Sustainability Profile
Juno Therapeutics, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States, with significant operations across various regions. Founded in 2013, the company has rapidly established itself as a leader in the development of innovative cell therapies, particularly in the field of oncology. Juno is renowned for its pioneering work in CAR T-cell therapy, which harnesses the body’s immune system to target and eliminate cancer cells. This unique approach has led to groundbreaking treatments that have transformed patient outcomes in certain blood cancers. With a strong market position, Juno Therapeutics has achieved notable milestones, including successful clinical trials and partnerships that enhance its research capabilities. The company continues to push the boundaries of cancer treatment, striving to deliver life-changing therapies to patients worldwide.
DitchCarbon Score
How does Juno Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Juno Therapeutics, Inc.'s score of 53 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Juno Therapeutics, Inc.'s reported carbon emissions
In 2023, Juno Therapeutics, Inc., headquartered in the US, reported no specific carbon emissions data, including Scope 1, 2, or 3 emissions. The company has not disclosed any absolute emissions figures for the years 2021 to 2023, indicating a lack of detailed reporting on their carbon footprint. Juno Therapeutics is a current subsidiary of Bristol-Myers Squibb Company, which may influence its climate commitments and reporting practices. However, no specific reduction targets or climate pledges have been identified for Juno Therapeutics. The absence of disclosed emissions data suggests that the company may be in the early stages of developing its climate strategy or may rely on its parent company's initiatives for guidance. As part of the broader industry context, Juno Therapeutics is expected to align with the sustainability goals set by Bristol-Myers Squibb, which may include commitments to reduce carbon emissions and enhance environmental stewardship. However, without specific data or targets from Juno itself, the details of its climate commitments remain vague.
How Carbon Intensive is Juno Therapeutics, Inc.'s Industry?
How Carbon Intensive is Juno Therapeutics, Inc.'s Location?
Juno Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Juno Therapeutics, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
